Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

RXi finding growth in tighter RNAi focus

August 9, 2010 By Mass High Tech: The Journal of New England Technology

RXi Pharmaceuticals Corp. is at a crossroads.

The small Worcester-based company, potentially on the cutting edge of one of biology’s most promising frontiers, struggled through the recession as many early-stage public biotech companies did: with little cash and wavering investor confidence.

But in the past few months, the company has narrowed its therapeutic focus to eye and skin diseases, won a $600,000 grant from the National Institutes of Health, signed a deal with a global corporate partner and sought to shore up its share price by diversifying its investor portfolio.

RXi has, until now, conducted early-stage preclinical work in RNA interference. RNAi prevents genes from producing disease-causing proteins by binding to and destroying targeted messenger RNA molecules to silence the bad gene. Researchers believe shutting off these genes could treat a variety of diseases.

The company announced in June it would narrow its focus, initially, to skin and eye conditions, because the company feels most confident about the delivery methods for the technology in those areas.

CEO Noah Beerman said the company planned to file two Investigational New Drug applications — the first step in the U.S. regulatory process — by 2012. The company is pursuing a drug candidate to treat scarring and estimates that the potential market in the U.S. is up to $4 billion with approximately 42 million skin-scarring surgical procedures annually.

In ophthalmology, the company plans to pursue several eye diseases that, when combined, affect approximately 18 million people in the United States and have an estimated market potential of up to $20 billion, Beerman said.

“Like a lot of new trends in biotech, initially, there is a lot of excitement. Then people get working on it and realize it’s 20 years to get somewhere,” said Steve Yoo, vice president at Boston boutique life sciences bank Leerink Swann.

Yoo said that the small number of human trials and lack of long-term safety studies in the field are beginning to weigh on investors.

RXi (Nasdaq: RXII) is working to blunt against potential weariness in the market. The company announced a partnership with Netherlands-based Royal Philips Electronics, whose health-care division has a strong presence in ultrasound technology, to pursue image-guided drug delivery as a potential way to administer RNAi therapies. Financial terms were not disclosed.

This type of narrow partnership is likely to become more common in the RNAi field, analysts say, as big corporate partners become more wary of broad technology platform deals with no specific focus.

RXi has a challenge outside of advancing its technology and attracting partners, and that is to diversify its portfolio of investors. The company spun off from Los Angeles-based CytRx Corp. in 2007, which had owned almost half of the company until the last several months.

“There has been selling pressure on the stock, not because of the fundamentals of the company, but because CytRx has sold 2 million out of its 5 million shares,” Beerman said.

He added that both sides are working to reduce CytRx share of the company and diversify its investor mix, in a methodical way. To that end, last month, investor Kevin Tang and his associated companies bought 952,369 shares of RXi, 5.18 percent, according to regulatory documents.

RXi employs about 30 people and plans to hire about a half-dozen more. The company had a net loss of $3.9 million in the first quarter of 2010, down from a loss of $4.2 million for the corresponding period last year. The company had cash and cash equivalents of $14.8 million on March 31, up from $14.8 million on Dec. 31, 2009.

RXi’s stock closed at $2.31 on Tuesday, up a penny from the previous close of $2.30. The company’s stock has traded between $1.51 and $8.99 over the past year.

 

SOURCE

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe